Genmab — April 2017

[gentogen]

We demonstrate striking efficacy of dara monotherapy in 6 of 7 ETP-ALL samples with reduction of pb and splenic blasts

[gentogen]

Program Planner

(www.abstractsonline.com)

[gentogen]

2644 / 3 - SY-1425, a selective RARα agonist, induces high levels of CD38 expression in RARA-high AML tumors creating a susceptibility to anti-CD38 therapeutic antibody treatment

[gentogen]

By inducing the expression of CD38, SY-1425 in combination with DARA elicits tumor cell death and NK cell activation. Based on these findings, a phase 2 clinical study with SY-1425 in combination with an anti-CD38 antibody is planned in AML using an RARA biomarker patient selection strategy.

[gentogen]

Program Planner

(www.abstractsonline.com)

[gentogen]

The combination of SY-1425 and DARA led to a six-fold increase in tumor cell death relative to the single agent controls, and 5-10 fold increases in NK cell activation is observed only in the SY-1425 and DARA combination treatment of RARA-high AML cell lines.

[Bulder]

Hold da op. Du har haft travlt gentogen. Så hvad har vi nu? Et præklininsk studie, der påpeger synergi mellem dara og CS1-CAR NK celler i MM. Og dara mono i T-ALL. Et fase 1 studie er planlagt. Samt en kombination af SY-1425 og dara i AML. Et fase 2 studie er planlagt.

[E_L]

good find again. we discussed the middle one, SY-1425, on the back of a Yahoo article last week, i think Thursday. It must be this study that they will expand to include Dara: https://clinicaltrials.gov/ct2/show/NCT02807558?term=NCT02807558&rank=1

[E_L]

I could imagine Syros would want to
present this at ASCO also

[Mcjean]

It should pop up on CCN soon;-)

[Mcjean]

i wonder how good six-fold is and 5-10 fold increases in NK cell?

[E_L]

Is that new, the Cable Copenhagen Network ?

[Mcjean]

1-0

[royal]

Juve

[Bulder]

Alcyone er opdateret 7/4. Antallet af lokationer er - siden januar - udvidet fra 179 til 209. Ud af de 209 lokationer er 29 "completed". Ud af 12 US-lokationer er 7 "completed". https://www.clinicaltrials.gov/ct2/show/study/NCT02195479?term=daratumumab+and+velcade&rank=1&show_locs=Y#locn

[KWC]

Tak Gento for update..

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

With an estimated enrolment of 700 patients for Alcyone, that would only be 3-4 patients per location. Do you think enrolment will stop when 700ish is reached or does each location need to make its minimum?